Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants

15 Dec 2021

Abstract excerpt

Abstract Measuring the level of protection conferred by anti-SARS-CoV-2 (trimeric) spike or RBD (receptor binding domain) antibodies (especially total and IgG) is a suitable and reliable approach for predicting biological protection against the risk of infection and severe coronavirus disease 2019 (COVID-19) illness. Nonetheless, SARS-CoV-2 has undergone a broad process of recombination since the identification...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34911171
DOI: 10.1515/cclm-2021-1287

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variantsPMID 34911171Read ↗

The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesSemantic proximity Read ↗

Serological testing for SARS-CoV-2 antibodies in clinical practice: a comparative diagnostic accuracy studySemantic proximity Read ↗

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsSemantic proximity Read ↗

Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology TestsSemantic proximity Read ↗

Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19Semantic proximity Read ↗

Improved diagnosis of SARS-CoV-2 by using Nucleoprotein and Spike protein fragment 2 in quantitative dual ELISA testsSemantic proximity Read ↗

Reduced sensitivity of commercial Spike-specific antibody assays after primary infection with the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

A comprehensive antigen production and characterization study for easy-to-implement, highly specific and quantitative SARS-CoV-2 antibody assaysSemantic proximity Read ↗

Evaluation of Commercial Anti-SARS-CoV-2 Neutralizing Antibody Assays in seropositive subjectsSemantic proximity Read ↗

Quantitative measurement of IgG to SARS-CoV-2 proteins using ImmunoCAPSemantic proximity Read ↗

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsSemantic proximity Read ↗

Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.